Your browser doesn't support javascript.
loading
Multiple micronutrient supplements versus iron-folic acid supplements and maternal anemia outcomes: an iron dose analysis.
Gomes, Filomena; Agustina, Rina; Black, Robert E; Christian, Parul; Dewey, Kathryn G; Kraemer, Klaus; Shankar, Anuraj H; Smith, Emily R; Thorne-Lyman, Andrew; Tumilowicz, Alison; Bourassa, Megan W.
Afiliación
  • Gomes F; The New York Academy of Sciences, New York, New York.
  • Agustina R; NOVA Medical School, Lisbon, Portugal.
  • Black RE; Department of Nutrition, Faculty of Medicine, Universitas Indonesia - Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
  • Christian P; Human Nutrition Research Centre, Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Dewey KG; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Kraemer K; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Shankar AH; University of California, Davis, Davis, California.
  • Smith ER; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Thorne-Lyman A; Sight and Life Foundation, Basel, Switzerland.
  • Tumilowicz A; University of Oxford, Oxford, UK.
  • Bourassa MW; Summit Institute for Development, Mataram, Indonesia.
Ann N Y Acad Sci ; 1512(1): 114-125, 2022 06.
Article en En | MEDLINE | ID: mdl-35218047
ABSTRACT
Antenatal multiple micronutrient supplements (MMS) are more effective than iron and folic acid (IFA) supplements in reducing adverse pregnancy outcomes. Questions remain, however, about the ability of MMS to prevent anemia as effectively as IFA, especially at a lower dose of daily iron and in areas of high anemia prevalence. Analyzing data from 11 trials from a recent Cochrane review, we compared MMS to IFA, delivering either 30 or 60 mg of iron, in sustaining hemoglobin and preventing third trimester anemia and iron deficiency anemia (IDA), accounting for daily iron dose, total supplemental iron intake, and baseline prevalence of anemia. There were no differences between MMS and IFA in third trimester hemoglobin concentration or risks of anemia or IDA by iron dose or total supplemental iron consumed. MMS providing 30 mg of iron was comparable to IFA with 60 mg of iron mean hemoglobin difference of -0.26 g/L (95% CI -1.41 to 0.89), risk ratios of 0.99 (95% CI 0.92-1.07) for anemia, and 1.31 (95% CI 0.66-2.60) for IDA. Baseline prevalence of anemia did not explain heterogeneity in findings. Compared to IFA, MMS results in comparable hemoglobin concentration and protection against anemia during pregnancy, independently of iron dose.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anemia Ferropénica / Anemia Tipo de estudio: Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Ann N Y Acad Sci Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anemia Ferropénica / Anemia Tipo de estudio: Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Ann N Y Acad Sci Año: 2022 Tipo del documento: Article